Over the past two decades, advances in immunomodulatory and biologic therapies have significantly improved clinical and endoscopic remission rates in IBD. However, many patients continue to experience fatigue, anxiety, depression and impaired quality of life, even during apparent disease remission. This discrepancy highlights the need for a holistic approach—one that acknowledges the complex interplay between immunological, psychological, nutritional and social determinants of health. Despite increasing recognition of its importance, holistic care in IBD remains under-researched and inconsistently implemented. Rigorous, interdisciplinary research is essential to define, validate and integrate holistic interventions within evidence-based clinical frameworks.

IBD pathogenesis involves a dynamic interaction between genetic susceptibility, environmental triggers, immune dysregulation and microbiome alterations. Yet, disease experience extends far beyond mucosal inflammation. Up to 40%–60% of patients report persistent fatigue, 25%–35% meet criteria for anxiety or depression and many struggle with chronic pain and body image disturbance. The biopsychosocial model, first proposed by Engel [1], offers a valuable framework for IBD care and emphasises the interdependence of biological mechanisms and psychosocial context. Contemporary research must operationalise this model to improve disease understanding and management.

Several pilot and randomised studies have demonstrated benefits of mindfulness-based stress reduction, cognitive behavioural therapy and exercise programmes in improving quality of life and reducing perceived stress in IBD patients. Mikocka-Walus et al. [2] reported that psychological interventions significantly improved emotional well-being, even without measurable changes in disease activity. Digital health programs, including the IBD-BOOST trial, show feasibility of remote, scalable support interventions targeting fatigue and self-management. Similarly, dietary and lifestyle interventions, such as anti-inflammatory diets and structured physical activity, are associated with improved remission rates and lower corticosteroid dependency in observational cohorts . Despite these encouraging findings, evidence synthesis remains challenging due to heterogeneity in study design, endpoints and sample size.

To integrate holistic care into standard IBD management, future research must:

1. Standardise holistic outcomes by developing validated tools to measure fatigue, coping, resilience and social participation alongside endoscopic and biochemical indices.
2. Promote interdisciplinary collaboration by uniting gastroenterologists, psychologists, dietitians, behavioural scientists and data analysts in multicentre networks.
3. Leverage technology by utilising digital phenotyping, wearable devices and artificial intelligence to capture real-world data on behaviour, sleep and stress.
4. Ensure inclusivity by designing culturally sensitive, patient-centered studies reflecting diverse populations and socioeconomic contexts. 
5. Demonstrate cost-effectiveness by quantifying healthcare utilisation, hospitalisation rates and productivity gains associated with holistic approaches.

Integrating holistic principles into practice requires structured implementation strategies. Multidisciplinary IBD clinics that combine gastroenterology, nutrition and mental health services show promise in early models. Patient empowerment programmes and shared decision-making improve adherence and satisfaction. Education and training in psychosocial assessment for clinicians can close the gap between medical remission and patient-perceived wellness. ECCO has called for standardised patient-reported outcomes that capture emotional and social domains.

Holistic care in IBD embodies a paradigm shift from inflammation control to whole-person health. While the conceptual framework is well established, empirical validation remains urgently needed. Research that systematically evaluates biological, psychological and social dimensions of care will not only refine clinical practice but also redefine what constitutes successful treatment in IBD. The future of IBD therapy lies not only in targeting cytokines, but in understanding the human context in which inflammation persists.